| URL | https://www.fiercepharma.com/manufacturing/sales-n |
| Source | Fierce Pharma |
| Date Published | 10/23/2025 |
| Author Name | Kevin Dunleavy |
| Company/Division name | Galderma |
| Parent company | Galderma Group AG |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Capital investment ($): | 650 |
| Country(ies) from which reshored: | Switzerland |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals; dermatology |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies |